PDCD1 and neoplasm: These therapies are monoclonal antibodies which target cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), or programmed cell death ligand 1 (PD-L1) and reduce tumor-induced T-cell suppression (1, 2).